Weekly Rundown: Abridge poised for broader VA expansion; Hims & Hers builds out AI-native careSeptember 25, 2026
General EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapiesBy Healthcare Propulsion StaffSeptember 24, 20260 Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the…
